Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAOA | P21397 | 1/20 | 0.61 |
| ▸ | HTR2A | P28223 | 2/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.50 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.50 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.50 |
| ▸ | IDO1 | P14902 | 1/20 | 0.47 |
| ▸ | SIGMAR1 | Q99720 | 2/20 | 0.46 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.43 |
| ▸ | CA2 | P00918 | 1/20 | 0.43 |
| ▸ | CA9 | Q16790 | 1/20 | 0.43 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19472539 | 0.98 | MAOA (0.63) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL22873145 | 0.92 | HTR2A (0.50) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL469643 | 0.92 | MAOA (0.73) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL3246183 | 0.92 | MAOA (0.59) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| Hydrochloric Acid SCHEMBL9556361 | 0.91 | MAOA (0.70) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL10818930 | 0.90 | MAOA (0.69) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL22268839 | 0.89 | MAOA (0.67) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL3438742 | 0.84 | MAOA (0.65) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| Phenethylamine SCHEMBL7263898 | 0.84 | HTR2A (0.67) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 | |
| SCHEMBL4726492 | 0.84 | HTR2A (0.58) | MAOAHTR2ACYP2A6SMN1; SMN2TAAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110230555-A1 | Enzyme Inhibitors and the Use Thereof | DARA BIOSCIENCES, INC. | 2011-09-22 | — | — | US | disclosed |
| CN-102159080-A | Enzyme inhibitors and the use thereof | DARA BIOSCIENCES INC | 2011-08-17 | — | — | CN | disclosed |
| EP-2309859-A1 | ENZYME INHIBITORS AND THE USE THEREOF | Dara Biosciences, Inc. (US) | 2011-04-20 | — | — | EP | disclosed |
| WO-2010008473-A1 | ENZYME INHIBITORS AND THE USE THEREOF | DARA BIOSCIENCES, INC. (US) | 2010-01-21 | — | — | WO | disclosed |
| US-7402673-B2 | Diamine β2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2008-07-22 | — | — | US | disclosed |
| US-20080039495-A1 | Diamine Beta2 Adrenergic Receptor Agonists | THERAVANCE BIOPHARMA R&D IP, LLC | 2008-02-14 | — | — | US | disclosed |
| EP-1751086-A2 | DIAMINE ß2 ADRENERGIC RECEPTOR AGONISTS | Theravance, Inc. (US) | 2007-02-14 | — | — | EP | disclosed |
| WO-2005121065-A2 | DIAMINE β2 ADRENERGIC RECEPTOR AGONISTS | THERAVANCE, INC. (US) | 2005-12-22 | — | — | WO | disclosed |
| US-20050272769-A1 | Diamine beta2 adrenergic receptor agonists | THERAVANCE, INC. (US) | 2005-12-08 | — | — | US | disclosed |
| EP-0220878-A2 | Ethanolamine compounds | GLAXO GROUP LIMITED (GB) | 1987-05-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050272769-A1 | Diamine beta2 adrenergic receptor agonists | ADRB2, ADRB1, ADRA2C | MAOA 294/4885HTR2A 104/4885CYP2A6 1232/4885 |
| US-20110230555-A1 | Enzyme Inhibitors and the Use Thereof | GAA, CYP17A1, HSD17B11 | MAOA 1208/4885HTR2A 4259/4885CYP2A6 720/4885 |
| US-20080039495-A1 | Diamine Beta2 Adrenergic Receptor Agonists | ADRB2, ADRB1, ADRA2C | MAOA 294/4885HTR2A 104/4885CYP2A6 1232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.